VNDA
Income statement / Annual
Last year (2023), Vanda Pharmaceuticals Inc.'s total revenue was $192.64 M,
a decrease of 24.27% from the previous year.
In 2023, Vanda Pharmaceuticals Inc.'s net income was $2.51 M.
See Vanda Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$192.64 M
|
$254.38 M
|
$268.68 M
|
$248.17 M
|
$227.19 M
|
$193.12 M
|
$165.08 M
|
$146.02 M
|
$109.93 M
|
$50.16 M
|
| Cost of Revenue |
$14.80 M |
$24.28 M |
$25.63 M |
$23.36 M |
$24.49 M |
$20.51 M |
$17.85 M |
$24.71 M |
$23.46 M |
$1.58 M |
| Gross Profit |
$177.84 M |
$230.10 M |
$243.05 M |
$224.80 M |
$202.70 M |
$172.61 M |
$147.24 M |
$121.31 M |
$86.46 M |
$48.57 M |
| Gross Profit Ratio |
0.92 |
0.9 |
0.9 |
0.91 |
0.89 |
0.89 |
0.89 |
0.83 |
0.79 |
0.97 |
| Research and Development
Expenses |
$76.82 M
|
$85.77 M
|
$75.36 M
|
$55.58 M
|
$48.65 M
|
$43.59 M
|
$38.55 M
|
$29.16 M
|
$29.15 M
|
$19.23 M
|
| General & Administrative
Expenses |
$112.38 M
|
$133.89 M
|
$117.35 M
|
$127.91 M
|
$126.54 M
|
$105.75 M
|
$123.84 M
|
$99.79 M
|
$84.53 M
|
$84.64 M
|
| Selling & Marketing
Expenses |
$500,000.00
|
$2.60 M
|
$6.70 M
|
$12.60 M
|
$3.20 M
|
$900,000.00
|
$1.30 M
|
$1.40 M
|
$3.40 M
|
$5.00 M
|
| Selling, General &
Administrative Expenses |
$112.88 M
|
$136.49 M
|
$124.05 M
|
$140.51 M
|
$129.74 M
|
$105.75 M
|
$123.84 M
|
$99.79 M
|
$84.53 M
|
$84.64 M
|
| Other Expenses |
$2.09 M |
$1.52 M |
$1.48 M |
$1.48 M |
$1.51 M |
$3.61 M |
$1.47 M |
$665,000.00 |
$320,000.00 |
$124,000.00 |
| Operating Expenses |
$191.80 M |
$223.77 M |
$200.89 M |
$197.57 M |
$179.89 M |
$150.87 M |
$164.14 M |
$139.88 M |
$126.65 M |
$106.13 M |
| Cost And Expenses |
$206.59 M |
$248.05 M |
$226.52 M |
$220.93 M |
$204.38 M |
$171.38 M |
$181.99 M |
$164.59 M |
$150.11 M |
$107.71 M |
| Interest Income |
$0.00 |
$0.00 |
$199,000.00 |
$4.42 M |
$6.22 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.01 M
|
$2.73 M
|
$2.84 M
|
$2.86 M
|
$2.89 M
|
$2.96 M
|
$2.98 M
|
$11.87 M
|
$12.97 M
|
$2.25 M
|
| EBITDA |
-$10.94 M
|
$9.06 M
|
$45.01 M
|
$30.10 M
|
$25.70 M
|
$24.69 M
|
-$13.92 M
|
-$6.70 M
|
-$26.63 M
|
-$54.77 M
|
| EBITDA Ratio |
-0.06 |
0.03 |
0.16 |
0.12 |
0.11 |
0.12 |
-0.09 |
-0.05 |
-0.25 |
-2.65 |
| Operating Income Ratio
|
-0.07
|
0.02
|
0.16
|
0.11
|
0.1
|
0.11
|
-0.1
|
-0.13
|
-0.37
|
0.4
|
| Total Other
Income/Expenses Net |
$20.29 M
|
$4.97 M
|
$199,000.00
|
$4.42 M
|
$6.22 M
|
$3.61 M
|
$1.47 M
|
$665,000.00
|
$320,000.00
|
$124,000.00
|
| Income Before Tax |
$6.34 M |
$11.30 M |
$42.36 M |
$31.66 M |
$29.03 M |
$25.35 M |
-$15.43 M |
-$17.91 M |
-$39.87 M |
$20.19 M |
| Income Before Tax Ratio
|
0.03
|
0.04
|
0.16
|
0.13
|
0.13
|
0.13
|
-0.09
|
-0.12
|
-0.36
|
0.4
|
| Income Tax Expense |
$3.83 M |
$5.03 M |
$9.21 M |
$8.32 M |
-$86.53 M |
$138,000.00 |
$136,000.00 |
$104,000.00 |
$0.00 |
-$77.62 M |
| Net Income |
$2.51 M |
$6.28 M |
$33.15 M |
$23.34 M |
$115.55 M |
$25.21 M |
-$15.57 M |
-$18.01 M |
-$39.87 M |
$20.19 M |
| Net Income Ratio |
0.01 |
0.02 |
0.12 |
0.09 |
0.51 |
0.13 |
-0.09 |
-0.12 |
-0.36 |
0.4 |
| EPS |
0.0437 |
0.11 |
0.6 |
0.43 |
2.17 |
0.5 |
-0.35 |
-0.41 |
-0.94 |
0.58 |
| EPS Diluted |
0.0436 |
0.11 |
0.58 |
0.42 |
2.11 |
0.48 |
-0.35 |
-0.41 |
-0.94 |
0.55 |
| Weighted Average Shares
Out |
$57.38 M
|
$56.46 M
|
$55.55 M
|
$54.43 M
|
$53.14 M
|
$50.86 M
|
$44.48 M
|
$43.45 M
|
$42.25 M
|
$34.77 M
|
| Weighted Average Shares
Out Diluted |
$57.56 M
|
$56.98 M
|
$56.92 M
|
$55.19 M
|
$54.85 M
|
$53.05 M
|
$44.74 M
|
$43.45 M
|
$42.25 M
|
$36.69 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
